Compare GOGO & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOGO | QTTB |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.2M | 450.1M |
| IPO Year | 2011 | 2018 |
| Metric | GOGO | QTTB |
|---|---|---|
| Price | $2.83 | $15.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $15.00 | $13.00 |
| AVG Volume (30 Days) | ★ 1.6M | 944.2K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $910,491,000.00 | $53,737,000.00 |
| Revenue This Year | $3.68 | N/A |
| Revenue Next Year | $3.60 | N/A |
| P/E Ratio | $35.38 | ★ N/A |
| Revenue Growth | ★ 104.74 | N/A |
| 52 Week Low | $2.77 | $1.62 |
| 52 Week High | $12.50 | $23.57 |
| Indicator | GOGO | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 32.14 | 53.91 |
| Support Level | N/A | $14.26 |
| Resistance Level | $4.89 | $16.78 |
| Average True Range (ATR) | 0.28 | 1.12 |
| MACD | -0.16 | -0.15 |
| Stochastic Oscillator | 4.30 | 52.17 |
Gogo Inc is a broadband connectivity service for the business aviation market. It provides a customizable suite of smart cabin systems for integrated connectivity, inflight entertainment, and voice solutions. It generates two types of revenue: service revenue consists of monthly subscription and usage fees paid by aircraft owners and operators for telecommunication, data, and in-flight entertainment services, and equipment revenue consists of proceeds from the sale of ATG and narrowband satellite connectivity equipment and is recognized when control of the equipment is transferred to OEMs and dealers, which generally occurs when the equipment is shipped. Geographically, it operates in United States; and International as well.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).